丁丙诺啡透皮贴剂治疗骨科中重度慢性疼痛1241例回顾分析
摘要
<正>疼痛是骨科常见的临床问题,WHO和国际疼痛学会把疼痛定义为:组织损伤或潜在组织损伤引起的不愉快感觉和情感体验。美国疼痛学会主席James CamPell在1995年提出将疼痛列为"第五大生命体征"[1]。疼痛在初始阶段得不到有效控制,
引文
[1]谭冠先.疼痛诊疗学[M].第2版.北京:人民卫生出版社,2008:2.
[2]Joshi GP,Ogunnaike BO.Consequences of inadequate PostoPerative Pain relief and chronic Persistent PostoP-erative Pain[J].Anesthesiology Clinics of North America,2005,23:2-136.
[3]老年慢性非癌痛诊疗共识编写专家组.老年慢性非癌痛药物治疗中国专家共识[J].中国疼痛医学杂志2016,22(5):321-325.
[4]Andrew R,Derry S,Taylor RS,et al.The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain[J].Pain Practice2014,14:79-94.
[5]Chen B,Li L,Connor D,et al.Prevalence and characteristics of chronic body pain in China:a national study[J].Springerplus,2016,5:1-6.
[6]Yang G,Wang Y,Zeng Y,et al.Rapid health transition in China,1990-2010:findings from the Global Burden of Disease Study 2010[J].Lancet,2013,381:1987-2015.
[7]Steiner D,Munera C,Hale M,et al.Efficacy and safety of buprenorphine transdermal system(BTDS)for chronic moderate to severe low back pain:a randomized,double-blind study[J].J Pain,2011,12:1163-1173
[8]Emmanouil R,Ste-Marie PA,Sampalis JS,et al.Real-life assessment of the validity of patient global impression of change in fibromyalgia[J].Rmd Open,2015,1:e000146.
[9]游永刚,徐永清,师继红,等.昆明某医院骨科门诊疾病谱调查分析[J].西南国防医药,2009,19:1321~1323.
[10]Plosker GL.Buprenorphine 5,10 and 20μg/h transdermal patch:a review of its use in the management of chronic non-malignant pain[J].Drugs,2011,71:2491-2509.
[11]Karlsson M,Berggren AC.Efficacy and safety of lowdose transdermal buprenorphine patches(5,10,and 20microg/h)versus prolonged-release tramadol tablets(75,100,150,and 200 mg)in patients with chronic osteoarthritis pain:a 12-week,randomized,open-label controlled,par[J].Clin Ther,2009,31:503-513.
[12]Conaghan PG,O'Brien CM,Wilson M,et al.Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee:a randomised trial[J].Osteoarthr&Cartilage,2011,19:930~938.
[13]冉凤鸣,臧爱华.重视阿片类镇痛药物的不良反应[J]药品评价,2012,9:42-44.
[14]American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons[J].JAm Geriatr Soc,2009,57:133~11346.
[15]Abdulla A,Adams N,Bone M,et al.Guidance on the management of pain in older people[J].Age and A-geing:The Journal of the British Geriatrics Society and the British Society for Research on Ageing,2013,(Suppl.1):i1-i57.
[16]Tan G,Jensen MP,Thornby JI,et al.Validation of the Brief Pain Inventory for chronic nonmalignant Pain[J]J Pain,2004,5:133-137.
[17]Patterson DR,Ptacek JT,Carrougher G,et al.The 2002Lindberg Award.PRN vs regularly scheduled opioid analgesics in Pediatric burn Patients[J].J Burn Care Rehabil,2002,23:424-430.
[18]NCCN Clinical Practice Guidelines in Oncology(Adult Cancer Pain)Version 2,2017.
[2]Joshi GP,Ogunnaike BO.Consequences of inadequate PostoPerative Pain relief and chronic Persistent PostoP-erative Pain[J].Anesthesiology Clinics of North America,2005,23:2-136.
[3]老年慢性非癌痛诊疗共识编写专家组.老年慢性非癌痛药物治疗中国专家共识[J].中国疼痛医学杂志2016,22(5):321-325.
[4]Andrew R,Derry S,Taylor RS,et al.The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain[J].Pain Practice2014,14:79-94.
[5]Chen B,Li L,Connor D,et al.Prevalence and characteristics of chronic body pain in China:a national study[J].Springerplus,2016,5:1-6.
[6]Yang G,Wang Y,Zeng Y,et al.Rapid health transition in China,1990-2010:findings from the Global Burden of Disease Study 2010[J].Lancet,2013,381:1987-2015.
[7]Steiner D,Munera C,Hale M,et al.Efficacy and safety of buprenorphine transdermal system(BTDS)for chronic moderate to severe low back pain:a randomized,double-blind study[J].J Pain,2011,12:1163-1173
[8]Emmanouil R,Ste-Marie PA,Sampalis JS,et al.Real-life assessment of the validity of patient global impression of change in fibromyalgia[J].Rmd Open,2015,1:e000146.
[9]游永刚,徐永清,师继红,等.昆明某医院骨科门诊疾病谱调查分析[J].西南国防医药,2009,19:1321~1323.
[10]Plosker GL.Buprenorphine 5,10 and 20μg/h transdermal patch:a review of its use in the management of chronic non-malignant pain[J].Drugs,2011,71:2491-2509.
[11]Karlsson M,Berggren AC.Efficacy and safety of lowdose transdermal buprenorphine patches(5,10,and 20microg/h)versus prolonged-release tramadol tablets(75,100,150,and 200 mg)in patients with chronic osteoarthritis pain:a 12-week,randomized,open-label controlled,par[J].Clin Ther,2009,31:503-513.
[12]Conaghan PG,O'Brien CM,Wilson M,et al.Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee:a randomised trial[J].Osteoarthr&Cartilage,2011,19:930~938.
[13]冉凤鸣,臧爱华.重视阿片类镇痛药物的不良反应[J]药品评价,2012,9:42-44.
[14]American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons[J].JAm Geriatr Soc,2009,57:133~11346.
[15]Abdulla A,Adams N,Bone M,et al.Guidance on the management of pain in older people[J].Age and A-geing:The Journal of the British Geriatrics Society and the British Society for Research on Ageing,2013,(Suppl.1):i1-i57.
[16]Tan G,Jensen MP,Thornby JI,et al.Validation of the Brief Pain Inventory for chronic nonmalignant Pain[J]J Pain,2004,5:133-137.
[17]Patterson DR,Ptacek JT,Carrougher G,et al.The 2002Lindberg Award.PRN vs regularly scheduled opioid analgesics in Pediatric burn Patients[J].J Burn Care Rehabil,2002,23:424-430.
[18]NCCN Clinical Practice Guidelines in Oncology(Adult Cancer Pain)Version 2,2017.